---
title: "4d Pharma PLC (DDDD.L) Jefferies Next Generation IBD Therapeutics Summit"
publisher: "Share Talk"
author: "sharetalk"
published: "2021-10-12T07:13:29+00:00"
modified: "2021-10-12T07:13:29+00:00"
date: 2021-10-12
canonical: "https://www.share-talk.com/4d-pharma-plc-dddd-l-jefferies-next-generation-ibd-therapeutics-summit/"
category: "Healthcare"
categories: ["Healthcare", "Pharmaceutical"]
tags: ["4d Pharma PLC", "asthma", "Axel Glasmacher", "Biotherapeutic", "Biotherapeutics", "Christophe Carite", "clinical trials.", "DDDD", "disease control", "Dr Alex Stevenson", "GERMANY", "immune cells", "Kenilworth", "Live", "Longevity", "Matthew Chen", "Merck & Co", "Merger", "MRx0518", "NASDAQ", "NJ", "pharmaceutical", "Philipps-University Marburg", "strain", "USA", "Vaccines"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&ssl=1"
format: "news"
language: "en-GB"
---

# 4d Pharma PLC (DDDD.L) Jefferies Next Generation IBD Therapeutics Summit

**Published:** October 12, 2021
**Author:** sharetalk
**Categories:** Healthcare, Pharmaceutical
**Tags:** 4d Pharma PLC, asthma, Axel Glasmacher, Biotherapeutic, Biotherapeutics, Christophe Carite, clinical trials., DDDD, disease control, Dr Alex Stevenson, GERMANY, immune cells, Kenilworth, Live, Longevity, Matthew Chen, Merck & Co, Merger, MRx0518, NASDAQ, NJ, pharmaceutical, Philipps-University Marburg, strain, USA, Vaccines
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&ssl=1)

---

**4D pharma to Participate in Jefferies Virtual Next Generation IBD Therapeutics Summit**

Leeds, UK, October 12, 2021 – **4D pharma plc (AIM: DDDD, NASDAQ, LBPS)** , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that 4D management will present at the Jefferies Virtual Next Generation IBD Therapeutics Summit being held on October 19, 2021.

A webcast of the presentation will be available on the ‘Events’ section of the 4D pharma website at [www.4dpharmaplc.com](http://www.4dpharmaplc.com) beginning Tuesday, October 19, 2021 at 8:00 a.m. ET (1:00 p.m. BST).

**About 4D pharma**

4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease.  4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma’s Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has five clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, and Blautix® in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programs include candidates for CNS disease such as Parkinson’s disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

For more information, refer to [https://www.4dpharmaplc.com](https://www.4dpharmaplc.com)

Contact Information:

4D pharma

Investor Relations: [ir@4dpharmaplc.com](mailto:ir@4dpharmaplc.com)

---

**Original URL:** https://www.share-talk.com/4d-pharma-plc-dddd-l-jefferies-next-generation-ibd-therapeutics-summit/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*